AstraZeneca PLC (LSE:AZN) signed an agreement to acquire respiratory preparations portfolio from Takeda Pharmaceutical Company Limited (TSE:4502) on January 29, 2018. As part of the transaction AstraZeneca PLC will acquire portfolio of all respiratory products made by Takeda Pharmaceutical Company Limited. The transaction is expected to close in first quarter of 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,285 JPY | -0.56% |
|
-0.63% | +5.70% |
17/07 | Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading | MT |
17/07 | Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.70% | 43.61B | |
+55.35% | 815B | |
+32.26% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.19% | 247B | |
+14.17% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- AstraZeneca PLC signed an agreement to acquire respiratory preparations portfolio from Takeda Pharmaceutical Company Limited.